XML 20 R8.htm IDEA: XBRL DOCUMENT

Liquidity	6 Months Ended
Dec. 31, 2025
Liquidity
Liquidity	2. Liquidity As of December 31, 2025, the Company had cash and cash equivalents of $47.9 million and an accumulated deficit of $279.7 million. The Company incurred negative cash flows from operating activities of $16.9 million for the six months ended December 31, 2025, and $28.9 million for the fiscal year ended June 30, 2025 (“fiscal year 2025”). The Company has incurred operating losses since its inception, and management anticipates that our operating losses will lessen in the near term due to revenue growth and the pursuit of ongoing cost efficiencies. The Company’s primary sources of capital to date have been from its registered direct offerings, ATM sales agreement with Virtu Americas, LLC, proceeds from awarded government contracts, and revenue from sales of its products. Management believes that the Company’s cash and cash equivalents as of December 31, 2025 and anticipated revenue from sales of our products, are sufficient to fund the Company’s operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.

Liquidity

6 Months Ended

Dec. 31, 2025

2. Liquidity

As of December 31, 2025, the Company had cash and cash equivalents of $47.9 million and an accumulated deficit of $279.7 million. The Company incurred negative cash flows from operating activities of $16.9 million for the six months ended December 31, 2025, and $28.9 million for the fiscal year ended June 30, 2025 (“fiscal year 2025”). The Company has incurred operating losses since its inception, and management anticipates that our operating losses will lessen in the near term due to revenue growth and the pursuit of ongoing cost efficiencies. The Company’s primary sources of capital to date have been from its registered direct offerings, ATM sales agreement with Virtu Americas, LLC, proceeds from awarded government contracts, and revenue from sales of its products.

Management believes that the Company’s cash and cash equivalents as of December 31, 2025 and anticipated revenue from sales of our products, are sufficient to fund the Company’s operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.